Ember Therapeutics, Inc.
EMBT
Other OTC0.00
USD
-NaN
- -
CIK
0001537900
ISIN
US29082W1099
Return %
Stock
S&P500
1Y
- -
19.01
3Y
0.00
65.48
5Y
-99.94
72.20
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Joseph Hernandez
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 135 East 57th Street New York City NY United States of America 10022
- IPO Date
- Oct 21, 2015
- CIK
- 0001537900
- Website
- embertx.com
- Similar Companies
- Business
- Ember Therapeutics, Inc. Ember Therapeutics, Inc. (EMBT) operates as a clinical-stage biopharmaceutical company focused on developing regenerative medicines utilizing bone morphogenetic protein-7 (BMP-7) and related BMP family members, variants, novel formulations, and delivery technologies. The company targets disease modification of osteoarthritis through cartilage regeneration; reversal of insulin resistance and treatment of metabolic disorders including obesity and type 2 diabetes; and inhibition or reversal of organ fibrosis in conditions such as chronic kidney disease and Alport syndrome. Its lead product candidates include MT-006, which has completed Phase 2a clinical trials for osteoarthritis; MT-007 and MT-008, both with completed preclinical trials for chronic kidney disease and Alport syndrome respectively; and MT-009, a preclinical candidate for metabolic diseases. Ember Therapeutics holds approximately 450 patents covering BMP-7 technologies, clinical data, and manufacturing processes acquired from Stryker Corporation. Founded in 2010 and headquartered at 135 East 57th Street, 24th Floor, New York, New York, the company conducts operations primarily in the United States within the pharmaceuticals and biotechnology sector, serving patients with musculoskeletal, metabolic, and fibrotic diseases. In recent developments, Ember Therapeutics maintains its core pipeline from historical strategic moves, including a 2015 merger with Mariel Therapeutics that diversified its BMP-7 applications across osteoarthritis, kidney fibrosis, and metabolic indications, and earlier acquisition of extensive BMP-7 intellectual property from Stryker Corporation. No major new partnerships, funding rounds, acquisitions, or product launches have been reported in the last 1-2 years as of late 2025. The company continues preclinical and clinical advancement of its BMP-7 based candidates without noted reorganizations or operational shifts.